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Summary:
Sixty-eight patients suffering from breast cancer,
ovarian cancer, lymphoma or multiple myeloma were
treated with high-dose chemotherapy and autologous
stem cell transplantation. They underwent placement of
a central venous port via the subclavian vein for deliv-
ery of chemotherapy and reinfusion of stem cells. All
patients were followed prospectively for device-related
and overall complications, comprising a total of 18 213
days in situ (median: 267 days, range: 90–480). One
patient experienced a pneumothorax (1.4%) spon-
taneously resolved, as an acute toxicity. Two patients
(2.8%, 0.1 episodes/1000 days of use) were forced to
have the port removed due to infection, caused by Strep-
tococcus mitis in one case, while the causative agent was
not identified by laboratory tests in the second. The
other 66 patients completed the therapeutic pro-
gramme, including peripheral stem cell reinfusions and
supportive care, such as i.v. antibiotics, antiemetics or
fluid administration and blood sample collection, with-
out additional complications. In conclusion, the use of
totally implantable central venous access ports has
resulted in good long-term access to central veins, in
spite of the severe neutropenia and increased septic risk
of this category of oncology patients.
Keywords: central venous catheters; ports; high-dose
chemotherapy; autologous stem cell transplantation
Central venous access is always necessary for the manage-
ment of patients undergoing high-dose chemotherapy
(HDCT) with concomitant BMT (bone marrow
transplantation) or autologous PBSCT (peripheral blood
stem cells transplantation). The systematic use of these
devices reduces the need to enter the venous system to draw
blood samples and administer cytotoxic drugs, antibiotics,
blood products, fluids, and nutrition, which are essential
parts of therapy. Moreover, high-flow venous catheters may
also be used for the collection of peripheral stem cells. Tun-
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neled, cuffed silastic catheters, first described by Broviac
et al1 and subsequently modified by Hickman et al2 provide
trouble-free function for most patients undergoing BMT
and currently represent the most frequently adopted intra-
venous line for these patients.3–5 The increased demand
among clinical oncologists for totally implantable access
ports (TIAP) in respect to percutaneous tunneled catheters
is motivated from the evidence that they need no external
dressing, allow patients normal activities improving their
quality of life and are easy to maintain on a 3-monthly
basis. Ports are now extensively used for delivering stan-
dard or infusional chemotherapeutic regimens in solid
tumors patients,6 whereas there are very few studies and
little data concerning the use of TIAP in patients undergo-
ing high-dose chemotherapy and PBSCT or BMT.7,8 A
possible explanation could be the fact that TIAP cannot be
easily withdrawn, unlike cuffed or non-tunneled catheters,
when an infectious catheter-related complication occurs. In
addition, the crude cost of TIAP is much higher than tun-
neled, cuffed external devices, although comparative and
comprehensive economic evaluations are not available to
date.9,10 Moreover, most studies do not involve a suf-
ficiently long follow-up, whereas it is well known that a
number of late port or tunneled catheter-related compli-
cations arise some weeks or even months after implan-
tation. Last, but not least, nobody has previously investi-
gated the possibility of using these devices not only to
administer chemotherapy but also for PBSC reinfusion and
supportive care. The aim of this study was to examine pro-
spectively the use of TIAPs, by presenting the experience
of a single institution with a single type of device in a
number of consecutive patients who underwent HDCT
and BMT.
Patients and methods
Sixty-eight cancer patients treated with HDCT and autolog-
ous stem cell transplantation at the European Institute of
Oncology in Milan during a 12-month period from 1 Janu-
ary to 31 December 1997 received a TIAP implant and
were followed prospectively for device-related and overall
complications. Patient characteristics and HDCT regimens
used are shown in Table 1.
All devices were placed in the operating room under
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Table 1 Population characteristics, types of tumors and chemo-
therapy programmes
No. of ports 68
No. of patients 68
Age (years, mean) 41.8
range 22–62
Male:female ratio 8:60
aSequential chemotherapy for lymphoma33 10
bL-PAM chemotherapy for myeloma34 1
cHigh-dose EC chemotherapy for breast cancer 15
dHigh-dose ICE chemotherapy for breast or ovarian cancer 35
Different high-dose chemotherapy for breast cancer 7
aCTX 7 g/m2 + MTX 8 g/m2 + VP-16 2 g/m2 + (Ida i.c. 15 mg/m2/day + L-
PAM 180 mg/m2 + PBSC support).
bAlkeran 200 mg/m2 + PBSC support in a single or double transplant.
cIphosphamide 2500 mg/m2 + carboplatin 300 mg/m2 + etoposide
300 mg/m2 + PBSC support repeated every 28 days for three cycles.
dEpirubicin 200 mg/m2 + cyclophosphamide 4 g/m2 + PBSC support
repeated every 28 days for three cycles.
fluoroscopic control by the same operator (RB); a single
dose of Cefazoline sodium (2 g) was given i.v. 15 min
before implantation. No breaks in operative technique or
instrument sterility were documented.
A single type of port was used, constructed from titanium
and silicone rubber, connected to a 7.8 F polyurethane cath-
eter (Port-A-Cath, SIMS Deltec, St Paul, MN, USA).
A confirmatory chest X-ray was always obtained after
the placement and a central venous access form was filled
in by the operator after the procedure. Data from the
follow-up of the patients were recorded on the form and
collected in a software registry. Follow-up was continued
until the device was removed, the patient died or the study
was closed (30 June 1998).
Complications were classified into two main categories:
(1) early (intraoperative and post-implantation period to
first use), and (2) late complications (occurring after the
first chemotherapy course given through the device).
Blood samples for microbiological analyses were
obtained when clinically indicated, in particular when
patients experienced fever with or without signs of systemic
sepsis. Criteria for the diagnosis of device-related bactere-
mia were defined as: (1) greater than a 10-fold increase in
colony-forming units (CFU) of bacteria per ml of blood
obtained through the device in comparison to peripheral
blood cultures; or (2) greater than 1000 CFUs of bacteria
obtained through the device, in the absence of peripheral
blood cultures; or (3) positive catheter tip culture upon
removal in the appropriate clinical setting. Device-related
bacteremia was considered cured when culture results were
negative on discontinuation of antimicrobic therapy and no
evidence of clinical infection occurred in the following 2
weeks.
Port pocket infection was defined as induration, ery-
thema, and tenderness around the port with culture-positive
material aspirated from the port pocket.
Cutaneous site infection was defined as induration, ery-
thema, or tenderness and exudate at the port surface needle
access site.
Thrombosis was detected with ultrasound and/or veno-
graphy when clinically suggested by progressive arm or
facial swelling.
Table 2 Duration of use of ports and route of central vein catheteriz-
ation
No. of ports 68
Days in situ (mean) 267
range 90–480
Days in situ (overall) 18,213
Percutaneous catheterizationa 62
Surgical venous cut-down (cephalic vein) 6 (10%)
aPercutaneous subclavian vein catheterisation first described by Aubaniac.28
Results
Sixty-eight devices were placed in 68 patients, resulting in
a total of 18 213 days in situ, and adequate follow-up was
obtained in all the cases (mean: 267 days, range: 90–480).
Table 2 summarizes pertinent device characteristics and
routes for central venous access. All patients received the
planned chemotherapy and re-infusion of stem cells
through the TIAP. We did not observe any TIAP-related
deaths in this series. An asymptomatic pneumothorax (less
than 30% of the pleural space) was observed as a compli-
cation of the TIAP placement in one patient, but this single
patient did not need any additional procedure except for
clinical observation and chest X-ray monitoring.
One patient in this series had an accidental arterial punc-
ture during the implantation procedure, which did not cause
any significant complications. If any doubt existed about
arterial vs venous cannulation, our policy was to withdraw
the wire and needle rather than risk the creation of a large
hole in the artery with a dilator.
No cases required early revision of the implant, for mal-
function of the catheter due to a narrowing of the lumen
or dislocation.
Late complications observed in our experience are listed
in Table 3. Interestingly, catheter rupture and embolization
did not occur at all and neither did clinically evident cath-
eter-associated venous thrombosis.
Port pocket infection, usually caused by gram-positive
cocci, suggests direct inoculation or migration of organisms
Table 3 Late complications observed in this series
Complication No. % of /1000 days Actions taken
devices of port use
Catheter rupture – migration 0
Symptomatic venous 0
thrombosis
Pocket infection 1 1.4 0.05 port removal
Skin erosion 0
Port-related bacteremiaa 1 1.4 0.05 antibiotics and
port removal
after
completing
the treatment
Total 2 2.8 0.10
Devices still in situ (30 June 49 72
1998)
aInfection was caused by Streptococcus mitis.
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along the accessing needle as the primary mechanism. It
occurred once in this series, 90 days after implant (1.4%,
0.05 episodes/1000 days of use); the causative agent was
not identified by laboratory tests, although a purulent dis-
charge was collected from the port subcutaneous pocket.
The device was removed and the infection successfully
cured, with no additional morbidity.
Nine patients developed febrile neutropenia of unknown
origin (FUO), while only one suffered from port-related
bacteremia (1.4%; 0.05 episodes/1000 days of port use),
due to Streptococcus mitis. The infection occurred 25 days
after the implant, and was successfully treated with appro-
priate systemic antibiotics; the port was removed after
completing the therapeutic programme.
Interestingly, all the patients received therapeutic support
through the port such as antiemetics, fluids, platelets and
red blood cells transfusions, antibiotics; blood samples
were regularly collected. No problems were reported during
or following these procedures. This resulted in a significant
improvement in the quality of life of the patients, allowing
them to move their arms and to attend to daily care more
easily. In four cases only out of 68 it was necessary to give
25 000 IU of urokinase to remove fibrin from the catheter
and restore normal flow through the device.
After discharge of the patient, the TIAP was washed with
normal saline just once every 3 months, and complete
function was maintained.
Discussion
Device-related morbidity reported in the literature is diffi-
cult to compare because of varying definitions and dissimi-
lar patient populations. Compared to tunneled catheters,
port infections tend to be unusual,11 even if results are
sometimes conflicting12 and most series reflect differences
in the type of device used and patients being treated, rather
than any inherent superiority of one device over another.
Moreover, it is likely that the patients requiring more inten-
sive treatment such as those with hematologic malig-
nancies, severe neutropenia or bone marrow transplants, are
candidates to receive tunneled double-lumen Hickman cath-
eters, which are much more easy to remove than are ports,
and allow high flow. The negative role of neutropenia was
emphasized by a study of nosocomial septicemia in cancer
patients, which reported that 61% of septic episodes in
patients with central venous lines occurred when the
patients were neutropenic.13 Moreover, high-dose chemo-
therapy, multiple blood tests and transfusions are more
feasible with a larger bore catheter. For these reasons, Hick-
man’s catheter or similar devices currently represent the
most frequently used intravenous lines for patients undergo-
ing bone marrow transplantation. While several retrospec-
tive studies have noted higher infection rates for external
devices compared to TIAP in selected patient popu-
lations,11,14, a prospective randomized study was unable to
demonstrate a statistically significant difference in inci-
dence of infections.15 They appeared much more common
for both Hickman catheters and ports than many other
reports, probably due in part to a study population that
included many patients with hematologic malignancies. In
a randomized study of infectious morbidity in patients with
solid tumors, TIAP have been shown to be associated with
fewer infections than were catheters.16 Most often, these
septic events are due to bacteremias that develop from sites
of microbial invasion remote from the catheter itself and
which usually respond to appropriate antibiotics without the
need for catheter withdrawal;17,18 removal may be neces-
sary for persistent or recurrent bacteremia or for fungal
infections. In spite of accurate implant procedure and
appropriate post-implantation care, catheter-related infec-
tions are reported in 11–45% of patients with Hickman
catheters,11,15,19,20 0–22% of patients with TIAP11,15,21,22 and
7–32% of patients with Groshong catheters.19,21,23,24,25 BMT
recipients are particularly prone to developing catheter-
related infectious complications; usually they exceed 20%
for subcutaneously tunneled devices.8,26 Non-tunneled cath-
eters have been recently proposed for patients undergoing
BMT,27 because they can be easily inserted and withdrawn
without surgery; conversely, they were associated with a
15% catheter-related infection rate. Data from this study,
derived from a prospective non-randomized study, support
the conclusions of most retrospective papers: the infectious
morbidity related to TIAP is very low, even in patients
undergoing cytostatic treatments for solid tumors. The
mechanisms of device-related infection may explain why
TIAP are less likely to be associated with infection than
are tunneled catheters. Migration of skin flora through the
cutaneous insertion site with catheter colonization is sup-
ported by the finding that gram-positive organisms,
especially coagulase-negative staphylococci are responsible
for a significant percentage of the cases of device-related
bacteremia in patients with catheters. Compared with cath-
eters, TIAP are irrigated less frequently, require no home
care, and are less prone to environmental or cutaneous con-
tamination when not accessed. All these factors may con-
tribute to the reduced incidence of infections associated
with TIAP.
Fluoroscopy has been always used at time of insertion of
the central venous catheter to immediately check the correct
position of the tip, even if post-implant confirmatory chest
X-ray is always obtained. Although the success rate of
‘blind’ insertion of the catheter may be quite high and this
approach could avoid the additional cost of ultrasound or
fluoroscopy, the routine use of fluoroscopy allowed us to
avoid time-consuming, patient-stressing and very expensive
repositioning of the device after post-implant radiologic
demonstration of its wrong location in the contralateral bra-
chiocephalic vein or in the ipsilateral internal jugular vein.
Moreover, since 1989 there has been a formal warning from
FDA-USA to avoid the intra-atrial location of the catheter
tip and this may be easily accomplished with the rigorous
use of fluoroscopic intraoperative control.
The incidence of symptomatic catheter-related venous
thrombosis was zero in this study (Table 3); no useful data
are available from retrospective analyses of clinical and
autopsy reports, where the incidence varied from 0 to
50%.29,30 In a controlled randomized trial, prospective ven-
ography was performed as part of a study of prophylactic
low-dose warfarin, with a symptomatic thrombosis rate in
untreated patients of 12.5% and an overall rate
(symptomatic + silent) of 38% (15 of 40).31 Another pro-
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spective study in cancer patients, using the same device
(Port-a-Cath subclavian venous catheter) reported 62%
upper extremity deep vein thrombosis in the control group,
and 6% in patients taking 2500 IU subcutaneous Fragmin
once daily for 90 days (relative risk 6.75; P = 0.002, Fisher
exact test.32) Clinical data derived from our study are not
fully comparable, due to different patient populations and
absence of regular US scan or phlebografic monitoring, thus
limiting the diagnosis of venous thrombosis to clinically
obvious cases; however, they do not support the routine use
of low dose anticoagulants in patients bearing a TIAP, at
least in this clinical setting (high-dose chemotherapy and
PBSCT).
From the patients’ point of view, use of these devices
results in a great improvement in quality of life, both during
hospitalization and at home, between chemotherapy cycles.
Since this patient population is often at high risk of relapse,
we suggest that the device is maintained in situ for at least
2 years, even though such a decision is always taken with
the patient, based on his/her compliance.
New to this report is the possibility of reinfusing PBSC
and transfusing platelets and blood via the TIAP, without
any significant complications. In conclusion, the use of tot-
ally implantable ports has resulted in good long-term access
to central veins and delivery of high-dose chemotherapeutic
regimens with concomitant autotransplantation of stem cell,
in spite of the severe neutropenia and increased septic risk
of this category of oncology patients. Although multicentric
randomized clinical trials are needed to define optimal
devices in this clinical setting, the results of this prospec-
tive, non-randomized study support a wider use of TIAP in
oncology patients undergoing high-dose chemotherapy and
autologous stem cell transplantation.
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